Drugs / Gamma Tocopherol
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00631085 | May 2008 → Jul 2009 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT00466596 | Mar 2007 → Nov 2013 | allergic rhinitis, asthma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT00386178 | Oct 2006 → Jun 2007 | asthma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT02104505 Comparator | Nov 2015 → Sep 2016 | allergic asthma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT03444298 Comparator | Jun 2018 → Mar 2023 | asthma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT02911688 Comparator | Sep 2016 → Feb 2019 | allergic asthma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gamma Tocopherol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00466596 ↗ |
| Known as | Vitamin E | “gamma tocopherol, a form of Vitamin E” NCT02911688 ↗ |
| Action | Inhibit | “γT inhibits Cyclooxygenase (COX)-2 and 5-Lipoxygenase (LO) in LPS-stimulated macrophages and interleukin (IL)-1b stimulated epithelial cells.” NCT02911688 ↗ |
| Route | Oral | “orally administered daily” NCT00386178 ↗ |